Sumimasa Nagai

MedicineEconomics, Econometrics and FinanceImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions”.

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

The Oncologist(2021)10.1002/onco.13713

N/A

0DataRank · unranked

2 citations

Sumimasa Nagai, Andrew C. Bennett, Shamia Hoque, Chadi Nabhan, Martin W. Schoen +18 more

Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies

The Lancet Haematology(2022)10.1016/s2352-3026(22)00045-x

N/A

0DataRank · unranked

24 citations

Lori M Minasian, Vishal Bhatnagar, Franco Cavalli, R Angelo De Claro, Amylou C Dueck +35 more